OBJECTIVE: To evaluate emotional processing in women with insulin-resistant polycystic ovary syndrome (IR-PCOS) and its relationship to glucose regulation and the mu-opioid system. DESIGN: Case-control pilot. SETTING: Tertiary referring medical center. PATIENT(S): Seven women with IR-PCOS and five non-insulin-resistant controls, aged 21-40 years, recruited from the general population. INTERVENTION(S): Sixteen weeks of metformin (1,500 mg/day) in women with IR-PCOS. MAIN OUTCOME MEASURE(S): Assessment of mood, metabolic function, and neuronal activation during an emotional task using functional magnetic resonance imaging (fMRI), and mu-opioid receptor availability using positive emission tomography (PET). RESULT(S): We found that insulin-resistant PCOS patients [1] had greater limbic activation during an emotion task than controls (n = 5); [2] trended toward decreased positive affect and increased trait anxiety; [3] after metformin treatment, had limbic activation that no longer differed from controls; and [4] had positive correlations between fMRI limbic activation during emotional processing and mu-opioid binding potential. CONCLUSION(S): Patients with IR-PCOS had greater regional activation during an emotion task than the controls, although this resolved with metformin therapy. Alterations in mu-opioid neurotransmission may underlie limbic system activity and mood disorders in IR-PCOS.
OBJECTIVE: To evaluate emotional processing in women with insulin-resistant polycystic ovary syndrome (IR-PCOS) and its relationship to glucose regulation and the mu-opioid system. DESIGN: Case-control pilot. SETTING: Tertiary referring medical center. PATIENT(S): Seven women with IR-PCOS and five non-insulin-resistant controls, aged 21-40 years, recruited from the general population. INTERVENTION(S): Sixteen weeks of metformin (1,500 mg/day) in women with IR-PCOS. MAIN OUTCOME MEASURE(S): Assessment of mood, metabolic function, and neuronal activation during an emotional task using functional magnetic resonance imaging (fMRI), and mu-opioid receptor availability using positive emission tomography (PET). RESULT(S): We found that insulin-resistant PCOS patients [1] had greater limbic activation during an emotion task than controls (n = 5); [2] trended toward decreased positive affect and increased trait anxiety; [3] after metformin treatment, had limbic activation that no longer differed from controls; and [4] had positive correlations between fMRI limbic activation during emotional processing and mu-opioid binding potential. CONCLUSION(S): Patients with IR-PCOS had greater regional activation during an emotion task than the controls, although this resolved with metformin therapy. Alterations in mu-opioid neurotransmission may underlie limbic system activity and mood disorders in IR-PCOS.
Authors: H S Mayberg; S K Brannan; R K Mahurin; P A Jerabek; J S Brickman; J L Tekell; J A Silva; S McGinnis; T G Glass; C C Martin; P T Fox Journal: Neuroreport Date: 1997-03-03 Impact factor: 1.837
Authors: Giuseppe Delvecchio; Philippe Fossati; Patrice Boyer; Paolo Brambilla; Peter Falkai; Oliver Gruber; Jarmo Hietala; Stephen M Lawrie; Jean-Luc Martinot; Andrew M McIntosh; Eva Meisenzahl; Sophia Frangou Journal: Eur Neuropsychopharmacol Date: 2011-08-05 Impact factor: 4.600
Authors: J K Zubieta; Y R Smith; J A Bueller; Y Xu; M R Kilbourn; D M Jewett; C R Meyer; R A Koeppe; C S Stohler Journal: Science Date: 2001-07-13 Impact factor: 47.728
Authors: M S George; E M Wassermann; W A Williams; A Callahan; T A Ketter; P Basser; M Hallett; R M Post Journal: Neuroreport Date: 1995-10-02 Impact factor: 1.837
Authors: Jennifer F Kawwass; Kristen M Sanders; Tammy L Loucks; Lisa Cencia Rohan; Sarah L Berga Journal: Hum Reprod Date: 2017-07-01 Impact factor: 6.918
Authors: Alison Berent-Spillson; Courtney Marsh; Carol Persad; John Randolph; Jon-Kar Zubieta; Yolanda Smith Journal: Psychoneuroendocrinology Date: 2016-09-05 Impact factor: 4.905